DBV Technologies, a biopharmaceutical company and Corporate Member of the Campaign, announced on November 5 that its product Viaskin™ Peanut (DBV712) has been validated by the European Medicines Agency (EMA). The validation confirms that the submission is sufficiently complete to begin the formal review process for the investigational non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
To read the full press release, please go here
Enter your details below and we’ll email you our printable guide featuring the symptoms to look out for and what to do in an emergency.
You’ll also receive our monthly Allergy Outlook email with our latest news, updates and resources straight to your inbox.